Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

The pipeline battle is far from over. Novo Nordisk is betting on CagriSema and next-generation amycretin-based therapies, which target multiple gut hormones to amplify weight-loss effects. Meanwhile, ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

The latest licensing agreements for early-stage candidates like Amycretin and others bought from Septerna and United Laboratories International show the company's transition away from peptide ...

In March 2005, the FDA granted a first-in-class approval to Amylin Pharmaceuticals’ amylin analogue pramlintide (Symlin) for type 2 diabetes. Just one month later, US regulators also approved ...

Monday, BMO Capital Markets maintained its "Market Perform" rating and a $64.00 price target for Novo Nordisk (NYSE: NVO) stock, a pharmaceutical giant with a market capitalization of $290.78 ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...